

**CASE STUDY**

**M&A TRANSACTIONAL ADVISORY**



**ALBANY MOLECULAR RESEARCH, INC. (NASDAQ: AMRI)**

Albany Molecular Research, Inc. (“AMRI”) is a contract research and manufacturing company providing integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company provides services within four segments; Discover & Development, Active Pharmaceutical Ingredients, Drug Product, and Fine Chemical. The company serves pharmaceutical and biotechnology companies; government research entities and non-profit organizations; and agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics businesses. It was founded in 1991 and is headquartered in Albany, New York.

**THE CARLYLE GROUP**

**THE CARLYLE GROUP L.P. (NASDAQ: CG)**

The Carlyle Group (“Carlyle”) is a global alternative asset manager with \$170 billion of assets under management across 299 investment vehicles. Founded in 1987 in Washington, DC, Carlyle has grown into one of the world’s largest and most successful investment firms, with more than 1,550 professionals operating in 31 offices in North America, South America, Europe, the Middle East, Africa, Asia and Australia.

**HOW BOURNE ADDS VALUE**

Bourne Partners provides strategic and financial advisory services to clients throughout the business evolution life cycle. We play an active role in helping businesses grow and maximize outcomes by creating long-term, profitable relationships that extend beyond single transactions. It is our focus on relationships and results that has yielded us an impeccable track record of client satisfaction.

**OBJECTIVE**


Bourne Partners (“Bourne”) has worked in partnership with The Carlyle Group since January 2016. Through this joint venture, Bourne advises and invests alongside Carlyle on various pharmaceutical and related services opportunities.

**PROCESS**

Bourne Partners utilized its relationships and knowledge of the CDMO and pharmaceutical sectors to provide counsel to The Carlyle Group in their evaluation and negotiation of the AMRI transaction.

**RESULT**

The Carlyle Group and GTCR LLC successfully acquired Albany Molecular Research, Inc. at a value of \$1.62 billion. The transaction officially closed on August 31, 2017.



“ The Bourne team worked diligently and added value in the evaluation and negotiation phases of the AMRI transaction. Their insight, experience and understanding of the CDMO and pharma sectors proved extremely useful and insightful. We also look forward to their investment and involvement alongside Carlyle in AMRI’s future growth strategy. ”

- Stephen Wise, Managing Director and Global Head of Healthcare, The Carlyle Group

<sup>1</sup> This testimonial may not be representative of the experience of other customers and is no guarantee of future performance or success